Compare iShares Core S&P 500 ETF (IVV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs BIO-TECHNE Corp — how do they compare? iShares Core S&P 500 ETF trades at $781.97 (market cap $897.20B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: iShares Core S&P 500 ETF is far larger — about 79× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and BIO-TECHNE Corp for 64 Days on average.
| IVV | TECH | |
|---|---|---|
Market Cap | $897.20B | $11.36B |
Volume | 4,580,672 | 5,390,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $72.61 |
52-Week Low | $634.93 | $43.31 |
Typical Hold Time | 46 Days | 64 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $781.97 with a slight 0.18% daily gain. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights mixed sentiment with concerns about profit growth slowing from 35% in 2026 to 15% in 2027 (24/7 Wall Street, 2026-10-03), though some analysts project a year-end rally (Citadel strategist, 2026-10-02). The ETF remains a core holding for broad market exposure amid ongoing economic uncertainties.
The outlook for IVV is cautiously optimistic, supported by bullish technicals and historical seasonal patterns. Key opportunities include potential upside from AI-driven earnings growth and index composition changes like Twilio's addition (Market Watch, 2026-10-01). Risks center on concentration in top holdings, rising interest rates, and geopolitical tensions that could dampen broader market performance. Investors should weigh the ETF's low-cost diversification against macroeconomic headwinds.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
